Author Correction to: Advances in anti-BRAF therapies for lung cancer

Affiliations

¹ Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, viale Pieraccini, 6, 50139, Florence, Italy. giandomenicoroviello@hotmail.it.
² Department of Biology & Biochemistry, University of Bath, BA2-7AX, Bath, UK.
³ Multidisciplinary Operative Unit of Mammary Pathology and Translational Research, ASST of Cremona, 26100, Cremona, Italy.
⁴ Department of Surgery and Cancer, Imperial College London, London, UK.
⁵ Department of Medicine, Section of Epidemiology and Population Sciences, Baylor College of Medicine, Houston, TX, 77030, USA.

Published Erratum

Giandomenico Roviello et al. Invest New Drugs. 2021 Oct.

. 2021 Oct;39(5):1456.

doi: 10.1007/s10637-021-01092-8.

¹ Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, viale Pieraccini, 6, 50139, Florence, Italy. giandomenicoroviello@hotmail.it.
² Department of Biology & Biochemistry, University of Bath, BA2-7AX, Bath, UK.
³ Multidisciplinary Operative Unit of Mammary Pathology and Translational Research, ASST of Cremona, 26100, Cremona, Italy.
⁴ Department of Surgery and Cancer, Imperial College London, London, UK.
⁵ Department of Medicine, Section of Epidemiology and Population Sciences, Baylor College of Medicine, Houston, TX, 77030, USA.

No abstract available

Erratum for

Advances in anti-BRAF therapies for lung cancer.
Roviello G, D'Angelo A, Sirico M, Pittacolo M, Conter FU, Sobhani N. Roviello G, et al. Invest New Drugs. 2021 Jun;39(3):879-890. doi: 10.1007/s10637-021-01068-8. Epub 2021 Jan 21. Invest New Drugs. 2021. PMID: 33474634 Free PMC article. Review.